Hansen D |
A randomised clinical study of alfacalcidol and paricalcitol. |
2012 |
Dan Med J |
pmid:22293059
|
Martin KJ and González EA |
Long-term management of CKD-mineral and bone disorder. |
2012 |
Am. J. Kidney Dis. |
pmid:22520454
|
Cozzolino M et al. |
VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH ≤ 150 pg/mL: results of the Italian FARO Survey. |
2012 |
Nephrol. Dial. Transplant. |
pmid:22523119
|
Fish RS and Cunningham J |
FGF-23 and vitamin D: don't shoot the messenger? |
2012 |
Nephrol. Dial. Transplant. |
pmid:22523113
|
Thadhani R et al. |
Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. |
2012 |
JAMA |
pmid:22337679
|
Anker SD and von Haehling S |
Vitamin D in chronic kidney disease: more questions than answers. |
2012 |
JAMA |
pmid:22337683
|
Cozzolino M et al. |
Role of vitamin d receptor activators in cardio-renal syndromes. |
2012 |
Semin. Nephrol. |
pmid:22365164
|
Park JW et al. |
Paricalcitol prevents cisplatin-induced renal injury by suppressing apoptosis and proliferation. |
2012 |
Eur. J. Pharmacol. |
pmid:22449373
|
Tonbul HZ et al. |
Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study. |
2012 |
Ren Fail |
pmid:22251408
|
Piao SG et al. |
Protective effect of paricalcitol on cyclosporine-induced renal injury in rats. |
2012 |
Transplant. Proc. |
pmid:22483459
|